Enasidenib (AG-221) is an oral small-molecule IDH2 inhibitor that is approved by FDA in 2017 for treatment of adult patients with mutant-IDH2 R/R AML at an initial dose of 100 mg once daily. The gene discussed is IDH2; the disease is acute myeloid leukemia.